Birth defects have become a significant public health issue affecting children's health and the quality of the birth population. China has an annual incidence of up to 900,000 new cases of birth defects, with certain defect rates displaying an upward trend.

According to the 'China Birth Defect Prevention and Control Report (2012)', it is estimated that over 130,000 new cases of congenital heart disease, approximately 35,000 cases of congenital hearing impairment, more than 7,600 cases of congenital hypothyroidism, and over 1,200 cases of phenylketonuria occur each year.

The goal of HaploX is to reduce birth defects and promote the birth of healthy babies through high-throughput sequencing technology for screening.